Emergent BioSolutions Inc. EBS R2K

Q: What is the current share price of Emergent BioSolutions Inc. (EBS)?

As of 2026-07-15 16:51 PDT, Emergent BioSolutions Inc. (EBS) trades at $7.89 on NYSE. Its 52-week range is $5.63 to $13.90.

Q: What is the market capitalisation of EBS?

Emergent BioSolutions Inc. (EBS) has a market capitalisation of $407.09M on NYSE.

Q: What is the P/E ratio of EBS?

EBS trades at a trailing price-to-earnings (P/E) ratio of -43.83. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 0.74.

Q: What is the return on equity (ROE) of EBS?

EBS has a return on equity (ROE) of -1.60%. Its return on capital employed (ROCE) is 8.44%.

Q: Is EBS a good stock to buy?

This page provides a data-driven analysis of Emergent BioSolutions Inc. (EBS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Drug Manufacturers - Specialty & Generic · United States

https://www.emergentbiosolutions.com

Company Profile ↓

$7.89

+8.08% 1Y

Mkt Cap$407.09M

P/E-43.83

P/B0.74

52W High$13.90

52W Low$5.63

Book Value$10.10

EPS (TTM)$-0.18

Company Overview

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Why Investors Should Care

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $742.90M (-28.8% YoY); net profit $52.60M.
Trailing 12 Months Year-on-year growth — revenue -29.7%, earnings -93.8%.
5-Year Trend Long-term compounding — revenue CAGR 7.5%, profit CAGR 3.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	7.46%
1 Year:	-29.70%

Compounded Profit Growth

5 Years:	3.33%
1 Year:	-93.80%

Stock Price Performance

1 Year:	+8.08%
6 Months:	-36.32%
3 Months:	-8.89%
1 Month:	-5.17%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 27% of range

$5.63 $13.90

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)45.18 · Neutral

Price Performance

1M-5.17%

3M-8.89%

6M-36.32%

1Y+8.08%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Generates positive free cash flow.

CONS

Trading 43.2% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-43.83

Industry PE

25.88

Forward P/E

2.64

PEG Ratio

0.38

Book Value

$10.10

Price to Book

0.74

P/S

0.57

EV/EBITDA

4.87

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

7.46%

Profit 5Y

3.33%

Revenue (YoY)

-29.70%

Earnings (YoY)

-93.80%

Profitability & Returns

ROCE

8.44%

ROE

-1.60%

ROA

3.43%

Profit Margin

-1.27%

Op Margin

6.79%

Gross Margin

47.49%

EPS (Latest Qtr)

$0.07

EPS (TTM)

$-0.18

Balance Sheet & Liquidity

Debt/Equity

1.12

Quick Ratio

1.90

Current Ratio

4.29

Debt

$584.60M

Total Assets

$1.32B

Current Assets

Working Capital

Ownership

Promoter Holding

3.85%

Chg in Prom Hold

FII / Inst Holding

86.92%

Chg in FII Hold

0.38%

Financial Snapshot

Enterprise Value

$407.09M

Total Revenue (TTM)

$676.80M

EBITDA

$166.70M

Free Cash Flow

$256.21M

Operating Cash Flow

$148.00M

Shares Outstanding

51.60M

Gross Margin

47.49%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	EBS Emergent BioSolutions Inc. R2K	7.89	-43.83	$407.09M	0.00%	8.44%	-1.60%	7.46%	3.33%
2	LLY Eli Lilly and Company SPX	1,156.63	41.13	$1.03T	0.60%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	247.02	28.66	$594.63B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.11	119.08	$431.29B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	418.52	31.54	$380.08B	2.18%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	123.61	34.82	$305.29B	2.82%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	168.37	26.10	$261.12B	1.87%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	535.29	29.40	$198.93B	0.35%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	358.32	24.92	$193.39B	2.80%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	116.90M	100.80M	149.40M	193.80M	117.80M	220.20M	173.70M	270.70M	190.60M	243.20M	311.80M	360.40M	192.50M	394.70M	385.20M	583.00M	343.00M	397.50M	-	-	-	-	-	-	-	300.40M	254.70M	293.80M	222.20M	140.90M	231.10M	156.10M
Gross Profit	-21.89M	35.10M	63.16M	65.15M	21.16M	-2.04M	35.48M	50.93M	14.90M	8.50M	47.80M	53.10M	-9.50M	66.80M	21.30M	11.20M	-27.40M	-7.00M	70.70M	77.80M	-	-	-	-	222.40M	144.30M	94.60M	142.00M	65.60M	75.30M	4.90M	140.70M	87.20M	147.80M	-48.00M	161.20M	-	-	-	-
Operating Income	-28.31M	21.45M	63.16M	49.89M	21.16M	-2.04M	35.48M	-	14.91M	8.53M	47.77M	-	-9.50M	66.80M	21.30M	-	-27.40M	-7.00M	70.70M	77.80M	-11.60M	126.00M	61.30M	258.10M	95.40M	14.50M	-34.70M	6.90M	-76.30M	-45.30M	-147.60M	-292.90M	-242.10M	39.80M	-203.50M	64.50M	49.90M	1.60M	76.50M	10.50M
Net Income	-21.52M	14.10M	36.94M	33.35M	3.99M	-10.95M	21.34M	-	10.48M	4.62M	33.55M	-	-4.90M	50.10M	20.90M	-3.40M	-26.10M	-9.50M	43.20M	46.90M	-12.50M	92.70M	39.50M	185.40M	69.70M	4.60M	-32.70M	-4.60M	-52.90M	-87.10M	-186.20M	-261.40M	-263.40M	9.00M	-283.10M	114.80M	68.00M	-12.00M	51.20M	6.80M
Diluted EPS	-0.57	0.32	0.79	0.71	0.10	-0.27	0.45	0.77	0.23	0.11	0.68	-	-0.10	0.98	0.41	-0.07	-0.51	-0.18	0.83	0.90	-0.24	1.73	0.73	3.44	1.28	0.09	-0.61	-0.09	-1.06	-1.75	-3.71	-5.16	-5.08	0.17	-5.38	2.06	1.19	-0.22	0.91	0.07
R&D Expense	38.70M	40.94M	34.18M	-	26.09M	27.89M	27.19M	-	20.48M	25.75M	22.66M	-	29.10M	24.70M	37.00M	-	46.10M	63.90M	53.40M	-	42.70M	47.90M	84.40M	-	52.50M	48.90M	49.60M	46.40M	49.80M	42.20M	40.70M	26.00M	15.30M	15.10M	32.70M	13.80M	15.10M	12.50M	13.50M	10.50M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	234.79M	286.17M	273.38M	281.89M	312.75M	450.14M	522.79M	488.80M	560.90M	782.40M	1.11B	1.56B	1.77B	1.12B	1.05B	1.04B	742.90M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	916.30M	891.30M	383.00M	317.60M	-	-
Operating Income	40.15M	73.56M	32.10M	29.97M	42.80M	89.19M	141.51M	105.50M	124.30M	89.80M	114.10M	433.80M	341.40M	-170.00M	-726.40M	-108.70M	100.10M
Net Income	31.14M	51.70M	23.02M	23.52M	31.14M	36.74M	62.87M	51.80M	82.60M	62.70M	54.50M	305.10M	219.50M	-211.60M	-760.50M	-190.60M	52.60M
Diluted EPS	0.99	1.59	0.64	0.65	0.85	0.88	1.41	1.13	1.71	1.22	1.04	5.67	4.06	-4.22	-14.85	-3.60	0.93
R&D Expense	74.59M	89.30M	124.83M	120.23M	119.93M	104.72M	119.19M	106.90M	97.40M	142.80M	226.20M	234.50M	235.20M	188.30M	111.40M	70.70M	53.20M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	500.32M	546.86M	564.23M	626.63M	938.69M	1.04B	970.11M	1.07B	2.23B	2.33B	2.88B	2.96B	3.17B	1.82B	1.39B	1.32B
Total Equity	199.35M	243.81M	369.46M	414.25M	441.36M	489.62M	553.20M	660.00M	596.20M	912.30M	1.01B	1.09B	1.45B	1.61B	1.39B	649.30M	482.80M	522.60M
Cash & Equivalents	91.47M	102.92M	169.02M	143.90M	141.67M	179.34M	280.50M	312.80M	271.50M	178.30M	112.20M	167.80M	621.30M	576.10M	642.60M	111.70M	99.50M	205.40M
Long Term Debt	-	-	30.24M	54.09M	58.30M	62.00M	251.00M	246.89M	248.09M	13.50M	784.50M	798.40M	841.00M	809.40M	448.50M	446.50M	663.70M	572.10M
Total Liabilities	-	-	126.76M	130.14M	122.10M	137.47M	385.49M	377.47M	373.91M	157.90M	1.22B	1.24B	1.44B	1.34B	1.78B	1.17B	906.90M	796.00M
Current Liabilities	-	-	75.72M	71.05M	61.91M	56.65M	92.94M	99.61M	105.86M	100.10M	200.40M	216.30M	384.50M	373.80M	1.23B	651.30M	162.40M	132.20M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	29.87M	98.02M	12.19M	39.64M	96.97M	112.32M	42.52M	54.60M	208.10M	41.80M	188.00M	536.00M	320.20M	-34.10M	-206.30M	58.70M	170.60M
Investing Cash Flow	-33.29M	-23.46M	-53.96M	-40.11M	-67.89M	-210.05M	-45.46M	-76.20M	-249.90M	-897.20M	-96.90M	-151.00M	-224.10M	-381.30M	212.30M	125.20M	69.40M
Financing Cash Flow	14.84M	-8.45M	16.66M	-1.76M	8.61M	198.87M	35.39M	-19.80M	-51.40M	788.70M	-35.90M	69.50M	-141.00M	481.20M	-535.70M	-190.00M	-136.60M
Capital Expenditure	-33.29M	-22.10M	-54.03M	-53.84M	-42.02M	-30.67M	-44.81M	-76.20M	-54.80M	-72.10M	-86.90M	-141.00M	-224.10M	-115.80M	-51.60M	-22.90M	-13.80M
Free Cash Flow	-3.42M	75.92M	-41.84M	-14.20M	54.95M	81.64M	-2.29M	-21.60M	153.30M	-30.30M	101.10M	395.00M	96.10M	-149.90M	-257.90M	35.80M	156.80M
Share Buybacks	-	0	0	5.91M	213.00K	200.00K	100.00K	0	33.10M	100.00K	0	0	106.00M	82.10M	0	0	24.90M

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	58.9%	50.3%	34.3%	30.3%	-	-
Operating Margin %	17.1%	25.7%	11.7%	10.6%	13.7%	19.8%	27.1%	21.6%	22.2%	11.5%	10.3%	27.9%	19.2%	-15.2%	-69.2%	-10.4%	13.5%
Net Margin %	13.3%	18.1%	8.4%	8.3%	10.0%	8.2%	12.0%	10.6%	14.7%	8.0%	4.9%	19.6%	12.4%	-18.9%	-72.5%	-18.3%	7.1%
ROE %	12.8%	14.0%	5.6%	5.3%	6.4%	6.6%	9.5%	8.7%	9.1%	6.2%	5.0%	21.0%	13.6%	-15.2%	-117.1%	-39.5%	10.1%
ROCE %	-	17.3%	6.7%	6.0%	7.5%	10.5%	15.1%	12.2%	12.8%	4.4%	5.4%	17.4%	13.2%	-8.8%	-62.0%	-8.9%	8.4%

Shareholding Pattern

Insiders

3.85%

Institutions

86.92%

Public Float

90.40%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	8.41%	4.34M	$32.56M
2	State Street Corporation	5.52%	2.85M	$21.37M
3	Dimensional Fund Advisors LP	5.34%	2.76M	$20.68M
4	American Century Companies Inc	4.70%	2.43M	$18.19M
5	Vanguard Capital Management LLC	4.38%	2.26M	$16.93M
6	Charles Schwab Investment Management, Inc.	2.92%	1.51M	$11.30M
7	Acadian Asset Management. LLC	2.68%	1.38M	$10.36M
8	Geode Capital Management, LLC	2.47%	1.27M	$9.55M
9	Palisade Capital Management, L.P.	2.33%	1.20M	$9.01M
10	Vanguard Portfolio Management LLC	2.17%	1.12M	$8.38M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for EBS

Google News ue, 14 Jul 2026

INO, MRNA, NVAX, EBS Jump Overnight: Trump Promises Full Hantavirus Report As Deadly Outbreak Sparks Vaccine Rally - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQd0ZHbWJ4R1lFVGhGQlByZ1FQNHFfUkNUV1pVX0dQSzNsWG9Zc2N0S2NweXZiYm0tdTBxQm9UeXNDcThCdmtjQjJwTE1CUDMxdXRqT1EwMmtHTHRMM2R6NjZtWG0zX0llUmo2cW1qVVZ6QXJfMVhMLWhUaVV5SWVaQWp5Q0ZrNlM5Z3ZabW…

Google News Wed, 01 Jul 2026

Erste Group Bank (WBAG:EBS) Stock Looks Undervalued As Its 384% 5 Year Run Continues - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPbEZCUWcyMEZCLWNRZUd6YmtnT0VRSHlXNXIwVUs4dlpIYkZqY0ZBWkgwN1BheEZHZFVONkdXZ0MyVnE5QTdNaDlWR0kxalpVcTN3YWdGLU81UXl4V1lrR0hzNURDd0s0NV9wLXlSWXBlTFZZVmpnM1UydUw0Qm9BSlZZZjR5RW1ZeVZXWm…

Google News Sun, 12 Jul 2026

Price-Driven Insight from (EBS) for Rule-Based Strategy - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNcDFTSEwwM1VURlREUnRqV2NQUHB6bkNNM3BGZExiSDdQUE1VTnJtQmx6c3NydGV3clhoZmJnTlR0TFBnUVBveDdyZzJMNHZFdTQzSE9kVHBFQ3lwekdGNHBsNmxxeHJKWkNhdUY0czlaeHJJSDVsVVZBbm1OdUVGaGFHenRVSVE4VHdmS0…

Google News Fri, 10 Jul 2026

ERSTE GROUP BANK AG (EBS.VI) Stock Chart - ChartMill

<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTE5CX0JyZWIzOVdZX3VmRVcteE5sY1BXc0hPQ1NjTVVjZVVTLXRxdlBUOTBxN1JNQ0Q3ZTZ2Tm5LTHZlLTVSZW5ld293c2JPdUR2RUk1c2xIY3FoMFYzUDYzUjI4N2pkWms?oc=5" target="_blank">ERSTE GROUP BANK AG (EBS.VI)…

Google News hu, 30 Apr 2026

Emergent BioSolutions (EBS) Stock Rises on Q1 2026 Earnings - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNajZWQklPYzc3NzlHRjh6Q2V2d0Z4SUcyU0lDdEZ1QXAzSDdibXUzR1R0SXIyVm5pcnk4RUdZZmw2V0RhaHpiLTJfb21VcTYxRzVqNXZjWHFQNUJJbEpMYVlyaU9XdFpPWW1jZV9ZN1VhSG9UX0RyVDRQX2xFU3JDTXZyTTVObnEzbmNVWW…

Google News Wed, 20 May 2026

Emergent BioSolutions execs line up Goldman Sachs, Jefferies investor talks - Stock Titan

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOanh5MXp2MVVHRjlBa0tqZ1FMQ09oZldKX3EzSXJMUlZiZk1Cd3dSckhud3o0NE9zZFFBMzh1V3FvbkExNGFNRjZDVWV6TXpLVExtSzItYkRIVXdYVG1NdVc0dzBZOXY3TTRuQjI5MThldkpDQkxLTkhJQk1aRWVodU95OHY0eW50NjJnZD…

EBS — Frequently Asked Questions

What is the current share price of Emergent BioSolutions Inc. (EBS)?

As of 2026-07-15 16:51 PDT, Emergent BioSolutions Inc. (EBS) trades at $7.89 on NYSE. Its 52-week range is $5.63 to $13.90.

What is the market capitalisation of EBS?

Emergent BioSolutions Inc. (EBS) has a market capitalisation of $407.09M on NYSE.

What is the P/E ratio of EBS?

EBS trades at a trailing price-to-earnings (P/E) ratio of -43.83. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 0.74.

What is the return on equity (ROE) of EBS?

EBS has a return on equity (ROE) of -1.60%. Its return on capital employed (ROCE) is 8.44%.

Is EBS a good stock to buy?

This page provides a data-driven analysis of Emergent BioSolutions Inc. (EBS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Emergent BioSolutions Inc. EBS R2K

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

INO, MRNA, NVAX, EBS Jump Overnight: Trump Promises Full Hantavirus Report As Deadly Outbreak Sparks Vaccine Rally - Stocktwits

Erste Group Bank (WBAG:EBS) Stock Looks Undervalued As Its 384% 5 Year Run Continues - Yahoo Finance

Price-Driven Insight from (EBS) for Rule-Based Strategy - Stock Traders Daily

ERSTE GROUP BANK AG (EBS.VI) Stock Chart - ChartMill

Emergent BioSolutions (EBS) Stock Rises on Q1 2026 Earnings - Quiver Quantitative

Emergent BioSolutions execs line up Goldman Sachs, Jefferies investor talks - Stock Titan

EBS — Frequently Asked Questions

What is the current share price of Emergent BioSolutions Inc. (EBS)?

What is the market capitalisation of EBS?

What is the P/E ratio of EBS?

What is the return on equity (ROE) of EBS?

Is EBS a good stock to buy?

Explore More